Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Paediatric Intensive Care Unit, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Influenza Other Respir Viruses. 2022 Nov;16(6):1059-1065. doi: 10.1111/irv.13044. Epub 2022 Aug 31.
This study aimed to understand the epidemiological and clinical characteristics of pediatric SARS-CoV-2 infection during the early stage of Omicron variant outbreak in Shanghai.
This study included local COVID-19 cases <18 years in Shanghai referred to the exclusively designated hospital from March 7 to March 31, 2022. Clinical data, epidemiological exposure, and COVID-19 vaccination status were collected. Relative risks (RRs) were calculated to assess the effect of vaccination on symptomatic infection and febrile disease.
A total of 376 pediatric cases of COVID-19 (median age: 6.0 ± 4.2 years) were referred to the designated hospital, including 257 (68.4%) symptomatic cases and 119 (31.6%) asymptomatic cases. Of the 307 (81.6%) children ≥3 years eligible for COVID-19 vaccination, 110 (35.8%) received two doses of vaccines. The median interval between the completion of two-dose vaccination and infection was 3.5 (interquartile range [IQR]: 3, 4.5) months. Compared with no vaccination, two-dose COVID-19 vaccination reduced the risks of symptomatic infection and febrile disease by 35% (RR 0.65, 95% confidence interval [CI]: 0.53-0.79) and 33% (RR 0.64, 95% CI: 0.51-0.81) among confirmed cases. Eighty-four percent of symptomatic cases had fever (mean duration: 1.7 ± 1.0.8 days), 40.5% had cough, and 16.4% had transient leukopenia. Three hundred and seven (81.6%) had an epidemiological exposure in household (69.1%), school (21.8%), and residential area (8.8%).
The surge of pediatric COVID-19 cases and multiple transmission model reflect wide dissemination of Omicron variant in the community. Asymptomatic infection is common among Omicron-infected children. COVID-19 vaccination can offer some protection against symptomatic infection and febrile disease.
本研究旨在了解奥密克戎变异株流行初期上海儿童 SARS-CoV-2 感染的流行病学和临床特征。
本研究纳入 2022 年 3 月 7 日至 3 月 31 日期间上海指定医院收治的本地 <18 岁 COVID-19 病例。收集临床数据、流行病学暴露和 COVID-19 疫苗接种情况。计算相对风险(RR)评估疫苗接种对有症状感染和发热疾病的影响。
共纳入 376 例 COVID-19 儿科病例(中位年龄:6.0±4.2 岁),包括 257 例(68.4%)有症状病例和 119 例(31.6%)无症状病例。在 307 例(81.6%)≥3 岁有资格接种 COVID-19 疫苗的儿童中,有 110 例(35.8%)接种了两剂疫苗。两剂疫苗接种完成与感染之间的中位间隔为 3.5(四分位距 [IQR]:3,4.5)个月。与未接种疫苗相比,两剂 COVID-19 疫苗接种可降低确诊病例中症状感染和发热疾病的风险 35%(RR 0.65,95%置信区间 [CI]:0.53-0.79)和 33%(RR 0.64,95% CI:0.51-0.81)。84%的有症状病例有发热(平均持续时间:1.7±1.0.8 天),40.5%有咳嗽,16.4%有短暂性白细胞减少症。307 例(81.6%)在家庭(69.1%)、学校(21.8%)和居民区(8.8%)有流行病学暴露。
COVID-19 病例的激增和多种传播模式反映了奥密克戎变异株在社区中的广泛传播。奥密克戎感染儿童中无症状感染很常见。COVID-19 疫苗接种可提供针对有症状感染和发热疾病的一定保护。